[CRIS] Curis, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 3.37 Change: 0.15 (4.66%)
Ext. hours: Change: 0 (0%)

chart CRIS

Refresh chart

Strongest Trends Summary For CRIS

CRIS is in the medium-term up 42% in 3 months. In the long-term down -94% below S&P in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Curis, Inc. is engaged in the research, development, and commercialization of cancer therapeutics. It focuses on developing cancer drug candidates, including CUDC-907, an oral, small molecule drug candidate that is designed to inhibit histone deacetylase and phosphatidylinositol-3-kinase, or PI3K enzymes; CUDC-427, an oral, small molecule drug candidate, which is designed to promote cancer cell death by antagonizing inhibitor of apoptosis proteins; Erivedge, an orally-administered small molecule Hedgehog pathway inhibitor; and Debio 0932, a small molecule inhibitor of heat shock protein 90. It has collaborations with Genentech, Inc. and F. Hoffmann-La Roche Ltd. for the development and commercialization of Erivedge. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -65.47% Sales Growth - Q/Q-16.81% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-37.73% ROE-51.38% ROI-41.08%
Current Ratio10.54 Quick Ratio Long Term Debt/Equity0.23 Debt Ratio0.11
Gross Margin96.5% Operating Margin-412.36% Net Profit Margin-440.57% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities64.06 M Cash From Investing Activities-40.58 M Cash From Operating Activities-7.76 M Gross Profit1.57 M
Net Profit-31.85 M Operating Profit-31.02 M Total Assets119.31 M Total Current Assets102.55 M
Total Current Liabilities9.73 M Total Debt27.38 M Total Liabilities31.69 M Total Revenue1.66 M
Technical Data
High 52 week4.9 Low 52 week0.62 Last close1.11 Last change1.83%
RSI37.21 Average true range0.08 Beta1.08 Volume507.06 K
Simple moving average 20 days-0.89% Simple moving average 50 days11.47% Simple moving average 200 days-29.85%
Performance Data
Performance Week6.73% Performance Month-15.91% Performance Quart-21.28% Performance Half-25%
Performance Year-55.39% Performance Year-to-date60.92% Volatility daily4% Volatility weekly8.94%
Volatility monthly18.32% Volatility yearly63.47% Relative Volume533.41% Average Volume375.06 K
New High New Low

News

2019-03-04 08:00:00 | Curis Announces Presentation at Cowen & Company 39th Annual Healthcare Conference

2019-02-04 07:00:00 | Curis, Inc. to Present at the 2019 BIO CEO & Investor Conference

2019-01-29 09:30:02 | Has Curis CRIS Outpaced Other Medical Stocks This Year?

2019-01-24 07:00:00 | First Mesothelioma Patient Dosed in CA-170 Study

2019-01-10 17:53:38 | First Eagle Slashes Curis Stake at Substantial Loss

2019-01-10 09:30:02 | Is Curis CRIS Outperforming Other Medical Stocks This Year?

2019-01-08 12:58:13 | Top 3 Healthcare Penny Stocks for 2018

2019-01-04 16:00:00 | Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2018-11-30 07:45:00 | Analysis: Positioning to Benefit within Dicerna Pharmaceuticals, Sun Life Financial, Autodesk, Eagle Pharmaceuticals, Curis, and Accenture — Research Highlights Growth, Revenue, and Consolidated Results

2018-11-20 10:45:00 | Curis to Present at the 60th Annual Meeting of the American Society of Hematology

2018-11-07 16:05:00 | Curis to Present at 33rd Society for Immunotherapy of Cancer Annual Meeting and Cowen IO NEXT Summit

2018-11-02 10:00:33 | Edited Transcript of CRIS earnings conference call or presentation 1-Nov-18 12:30pm GMT

2018-11-01 10:41:02 | Curis CRIS Reports Q3 Loss, Tops Revenue Estimates

2018-11-01 09:04:11 | Curis: 3Q Earnings Snapshot

2018-11-01 07:00:00 | Curis Reports Third Quarter 2018 Financial Results

2018-10-23 16:29:00 | Curis to Release Third Quarter Financial Results and Hold Conference Call on November 1, 2018

2018-10-23 08:45:00 | Investor Expectations to Drive Momentum within Ormat Technologies, The Andersons, Freshpet, Curis, Ultra Clean, and Edge Therapeutics — Discovering Underlying Factors of Influence

2018-10-19 10:39:02 | Curis CRIS Shares March Higher, Can It Continue?

2018-10-10 18:44:00 | Top 3 Healthcare Penny Stocks for 2018

2018-10-05 07:00:00 | Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2018-09-27 11:44:36 | Who Are The Top Investors In Curis Inc NASDAQ:CRIS?

2018-09-26 16:05:00 | Curis to Present at the Cantor Fitzgerald Global Healthcare Conference

2018-09-24 16:22:00 | Curis Announces Leadership Change

2018-08-29 07:45:00 | Report: Developing Opportunities within Q2, Ormat Technologies, The Andersons, Comstock Resources, Freshpet, and Curis — Future Expectations, Projections Moving into 2018

2018-08-28 16:14:00 | Curis to Present at the Baird 2018 Global Healthcare Conference

2018-08-02 11:50:03 | Curis CRIS Reports Q2 Loss, Lags Revenue Estimates

2018-08-02 11:11:48 | Edited Transcript of CRIS earnings conference call or presentation 2-Aug-18 12:30pm GMT

2018-08-02 10:45:41 | Curis: 2Q Earnings Snapshot

2018-08-02 07:00:00 | Curis Reports Second Quarter 2018 Financial Results

2018-07-27 08:30:00 | Curis to Release Second Quarter Financial Results and Hold Conference Call on August 2, 2018

2018-07-26 07:55:00 | Consolidated Research: 2018 Summary Expectations for At Home Group, Royal Bank Of Canada, Curis, Novavax, HNI, and Freshpet — Fundamental Analysis, Key Performance Indications

2018-07-23 09:18:00 | Top 3 Healthcare Penny Stocks for 2018

2018-07-09 10:33:00 | Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2018-06-11 09:32:07 | Benzinga Pro's 5 Stocks To Watch Today

2018-06-01 08:00:00 | Curis Shares Show Recent Gains, Pipeline Review and FDA Decision

2018-05-31 15:35:00 | Why Curis, Inc. Is Soaring Today

2018-05-31 08:27:47 | Benzinga Pro's 5 Stocks To Watch Today

2018-05-31 07:00:00 | /C O R R E C T I O N -- Curis, Inc./

2018-05-29 10:10:00 | Curis Announces Effectiveness of 1-for-5 Reverse Stock Split

2018-05-24 07:00:00 | Curis Expands Senior Management Expertise with Appointment of Robert Martell, M.D., Ph.D., as Head of Research and Development

2018-05-22 17:55:00 | Curis Announces 1-for-5 Reverse Stock Split

2018-05-21 08:30:00 | Factors of Influence in 2018, Key Indicators and Opportunity within MSA Safety Incorporated, Curis, American States Water, AAC, eHealth, and Vista Gold — New Research Emphasizes Economic Growth

2018-05-11 09:10:00 | Top 3 Healthcare Penny Stocks for 2018

2018-05-03 17:30:54 | Edited Transcript of CRIS earnings conference call or presentation 3-May-18 12:30pm GMT

2018-05-03 08:59:20 | Curis: 1Q Earnings Snapshot

2018-05-03 07:00:00 | Curis Reports First Quarter 2018 Financial Results

2018-04-26 07:00:00 | Curis to Release First Quarter 2018 Financial Results and Hold Conference Call on May 3, 2018

2018-04-20 17:30:33 | Are Earnings Prospects Improving For Loss-Making Curis Inc’s NASDAQ:CRIS?

2018-04-19 07:50:00 | Free Post Earnings Research Report: Curis’ Quarterly Revenue Jumped 38.10%

2018-04-06 07:00:00 | Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635c4